PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Starting soon
Conditions studied: Metastatic Prostate Cancer
In brief
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Key facts
- Study ID
- NCT07484269
- Run by
- Novartis Pharmaceuticals
- People needed
- 753
- Starts
- 2026-08-01
- Expected to finish
- 2031-07-31
- Last updated by the study team
- 2026-03-20
Who can join
Age: any. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years at index date
- Diagnosis of mPC
- PSMA positive
- Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date
- Exclusion criterion:
- Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.